New tool helps breast cancer patients navigate nerve damage risks

NCT ID NCT06915168

Recruiting now Symptom relief Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a decision aid for breast cancer patients experiencing nerve damage (numbness or tingling) from chemotherapy. The tool provides information about long-term nerve symptoms and helps patients discuss treatment priorities with their doctor. Researchers will enroll 20 patients to see if the aid improves decision-making and satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CIPN Decision Aid (informational tool)
What this could lead to: If it works, this tool could help breast cancer patients better understand and discuss nerve damage risks, leading to more informed treatment decisions.
What could go wrong: This is a very small, early-stage study with only 20 participants, so results may not apply to everyone. The tool is informational and does not directly treat or prevent nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

Contacts and locations

Locations

University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.